NCT00470158

Brief Summary

With the long-term public health goal of developing an effective micronutrient supplementation program to improve child health by improving iron and zinc status and decreasing morbidity due to diarrhea in areas with high rates of childhood malnutrition, we seek to determine the most efficacious method of decreasing childhood morbidity and mortality due to diarrhea in toddlers by re-examining the issue of iron and zinc interaction and determining if this interaction can be minimized by separate administration of iron and zinc supplementation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started May 2007

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2007

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

May 3, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 7, 2007

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2008

Completed
3.6 years until next milestone

Results Posted

Study results publicly available

September 19, 2011

Completed
Last Updated

April 20, 2018

Status Verified

December 1, 2009

Enrollment Period

9 months

First QC Date

May 3, 2007

Results QC Date

August 10, 2011

Last Update Submit

April 18, 2018

Conditions

Keywords

zincironinteractiondiarrheadelivery

Outcome Measures

Primary Outcomes (1)

  • Incidence of Diarrhea

    A diarrhea episode was defined as three or more loose, liquid, or watery stools for 2 consecutive days, separated in time from an earlier or subsequent episode by at least 2 consecutive diarrhea-free days.

    6 months

Secondary Outcomes (3)

  • Change in Hemoglobin

    6 months

  • Change in Zinc Status

    6 months

  • Percent Anemic

    6 months

Study Arms (5)

combined iron and zinc

EXPERIMENTAL

Iron and zinc together

Dietary Supplement: iron and zinc combined

Separate iron and zinc

EXPERIMENTAL

Iron and zinc on separate days

Dietary Supplement: iron and zinc on separate days

iron alone

EXPERIMENTAL

Iron

Dietary Supplement: iron

zinc alone

EXPERIMENTAL

Zinc

Dietary Supplement: Zinc

placebo

PLACEBO COMPARATOR
Dietary Supplement: placebo

Interventions

iron and zinc combinedDIETARY_SUPPLEMENT

Children \>= 12 months received an average of 5mg zinc/day, 6.25 Iron/day, and 25IU folic acid/day. children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.

Also known as: Tablets were manufactured by Nutriset, S.A.S. (Malaunay, France).
combined iron and zinc

Children \>= 12 months received an average of 5mg zinc/day, alternating daily with 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.

Also known as: Tablets were manufactured by Nutriset, S.A.S. (Malaunay, France).
Separate iron and zinc
ironDIETARY_SUPPLEMENT

Children \>= 12 months received an average 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.

iron alone
ZincDIETARY_SUPPLEMENT

Children \>= 12 months received an average of 5mg zinc/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.

zinc alone
placeboDIETARY_SUPPLEMENT

Children received daily placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.

placebo

Eligibility Criteria

Age6 Months - 18 Months
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Children 6-18 months old
  • Permanent residents of the selected villages

You may not qualify if:

  • Severe malnutrition requiring hospitalization (defined as weight for height \<-3 SD Z-score)
  • Severe anemia requiring treatment (hemoglobin \< 70 g/L)
  • Chronic illness that would impair feeding ability
  • Likely to move in next 6 months.
  • Fever greater than 38.5
  • Regular iron supplementation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ICDDR,B

Dhaka, Mohakhali, 1212, Bangladesh

Location

Related Publications (1)

  • Chang S, El Arifeen S, Bari S, Wahed MA, Rahman KM, Rahman MT, Mahmud AB, Begum N, Zaman K, Baqui AH, Black RE. Supplementing iron and zinc: double blind, randomized evaluation of separate or combined delivery. Eur J Clin Nutr. 2010 Feb;64(2):153-60. doi: 10.1038/ejcn.2009.127. Epub 2009 Nov 11.

MeSH Terms

Conditions

AnemiaDiarrhea

Interventions

IronZinc

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic DiseasesSigns and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Metals, HeavyElementsInorganic ChemicalsTransition ElementsMetals

Results Point of Contact

Title
Stephanie Chang
Organization
AHRQ

Study Officials

  • Robert E Black, MD, MPH

    Johns Hopkins Bloomberg School of Public Health

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 3, 2007

First Posted

May 7, 2007

Study Start

May 1, 2007

Primary Completion

February 1, 2008

Study Completion

February 1, 2008

Last Updated

April 20, 2018

Results First Posted

September 19, 2011

Record last verified: 2009-12

Locations